<DOC>
	<DOCNO>NCT00900887</DOCNO>
	<brief_summary>The purpose study determine efficacy ocular topic antiinflammatory therapy ( sodic nepafenac 0.1 % ketorolac 0.5 % ) treat center point thickness secondary selective photocoagulation diabetic clinically significant macular edema .</brief_summary>
	<brief_title>Topic Antiinflammatory Therapy Added Selective Photocoagulation Macular Edema</brief_title>
	<detailed_description>Selective photocoagulation standard treatment clinically significant macular edema . This treatment decrease incidence moderate visual loss long term . Nonetheless , first six week treatment induce , probably exacerbation macular edema secondary treatment . An inflammatory response report selective photocoagulation . Therefore , antiinflammatory therapy like ketorolac nepafenac could useful manage center point thickness secondary selective photocoagulation diabetic macular edema .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Ketorolac</mesh_term>
	<mesh_term>Ketorolac Tromethamine</mesh_term>
	<mesh_term>Nepafenac</mesh_term>
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<criteria>type 2 diabetes regardless diabetes duration retinopathy severity level one eye focal clinically significant macular edema treat selective focal photocoagulation visual capacity subjective refraction treatment adequate quality 6mm fast macular map day photocoagulation sign inform consent ocular surgery last 4 month previous selective photocoagulation topic systemic antiinflammatory therapy last week allergic antiinflammatory nonsteroid therapy lent contact use tha last 2 day photocoagulation history ocular trauma , ocular infection lacrimal dysfunction last 3 month history uveitis ocular inflammation last 12 month ocular external disease , infection inflammatory process evaluation corneal abnormality could modify visual capacity per se actual corneal disease pregnancy myopia 6.00 diopter retinal disease different diabetic retinopathy adverse event drug desert pharmacology therapy second visit assistance second visit inadequate quality 6mm fast macular map second visit</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>diabetic retinopathy</keyword>
	<keyword>clinically significant macular edema</keyword>
	<keyword>selective photocoagulation</keyword>
	<keyword>topic ketorolac</keyword>
	<keyword>topic nepafenac</keyword>
	<keyword>efficacy</keyword>
	<keyword>treatment</keyword>
</DOC>